Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.57 |
| ▸ | LTB4R | Q15722 | 6/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319665 | 0.92 | KMT2A (0.64) | KMT2ANPC1RAB9AALOX5LTB4R | |
| SCHEMBL12017300 | 0.89 | KMT2A (0.60) | KMT2ANPC1RAB9AALOX5LTB4R | |
| SCHEMBL8188967 | 0.89 | KMT2A (0.70) | KMT2ANPC1RAB9AALOX5LTB4R | |
| SCHEMBL17117230 | 0.88 | ALOX5 (0.71) | KMT2ANPC1RAB9AALOX5LTB4R | |
| SCHEMBL8506886 | 0.87 | KMT2A (0.57) | KMT2ANPC1RAB9ALTB4RLTB4R2 | |
| SCHEMBL12040759 | 0.86 | KMT2A (0.66) | KMT2ANPC1RAB9AALOX5LTB4R2 | |
| SCHEMBL7358726 | 0.86 | ALOX5 (0.59) | KMT2ANPC1RAB9AALOX5LTB4R | |
| SCHEMBL7426776 | 0.86 | KMT2A (0.57) | KMT2ANPC1RAB9AALOX5LTB4R | |
| SCHEMBL4064581 | 0.85 | KMT2A (1.00) | KMT2ANPC1RAB9AALOX5L3MBTL1 | |
| SCHEMBL4144964 | 0.85 | LTB4R (0.56) | KMT2ANPC1RAB9ALTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1911438-A2 | Cosmetic composition containing a derivative of dibenzoylmethane and a arylalkyl amide or ester compound; method of photostabilising the derivative of dibenzoylmethane | L'Oréal (FR) | 2008-04-16 | — | — | EP | disclosed |
| US-20080019930-A1 | Dibenzoylmethane sunscreens photostabilized with arylalkyl amide or ester compounds | L'OREAL (FR) | 2008-01-24 | — | — | US | disclosed |
| US-20080019930-A1 | Dibenzoylmethane sunscreens photostabilized with arylalkyl amide or ester compounds | L'OREAL (FR) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080019930-A1 | Dibenzoylmethane sunscreens photostabilized with arylalkyl amide or ester compounds | TYR, DDT, AADAC | KMT2A 1285/4885NPC1 1265/4885RAB9A 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.